Spots Global Cancer Trial Database for cobimetinib
Every month we try and update this database with for cobimetinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | NCT01959633 | Melanoma | Vemurafenib Peg-interferon Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer | NCT03340558 | Metastatic Colo... | Atezolizumab Cobimetinib | 18 Years - | Duke University | |
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations | NCT04409639 | Chronic Myelomo... | Cobimetinib | 18 Years - | University of Utah | |
| Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients | NCT03224208 | Melanoma Melanoma (Skin) Melanoma Stage | Vemurafenib Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | NCT03202940 | Non-small Cell ... | Alectinib Cobimetinib | 18 Years - | Massachusetts General Hospital | |
| Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC | NCT02303951 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital Tuebingen | |
| A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | NCT03273153 | Advanced BRAFV6... | Cobimetinib Atezolizumab Pembrolizumab | 18 Years - | Hoffmann-La Roche | |
| IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | NCT04109456 | Metastatic Mela... | IN10018 Cobimetinib Atezolizumab | 18 Years - | InxMed (Shanghai) Co., Ltd. | |
| Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors | NCT02639546 | Solid Tumors | Cobimetinib | 6 Months - 30 Years | Hoffmann-La Roche | |
| A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) | NCT03139513 | Melanoma | Cobimetinib Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | NCT03337698 | Carcinoma, Non-... | Atezolizumab Cobimetinib RO6958688 Docetaxel CPI-444 Pemetrexed Carboplatin Gemcitabine Linagliptin Tocilizumab Ipatasertib Bevacizumab Sacituzumab Gov... Radiation Evolocumab Tiragolumab XL092 Camonsertib | 18 Years - | Hoffmann-La Roche | |
| MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma | NCT04216953 | Sarcoma,Soft Ti... | Cobimetinib Atezolizumab | 12 Years - | Centre Leon Berard | |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | NCT03224767 | BRAF V600E Muta... Papillary Crani... | Vemurafenib Cobimetinib Laboratory Biom... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | NCT03281369 | Gastric Adenoca... | 5-Fluorouracil ... Leucovorin Oxaliplatin Atezolizumab Cobimetinib Ramucirumab Paclitaxel PEGylated recom... BL-8040 Linagliptin Atezolizumab Cobimetinib Cisplatin Tiragolumab 5-Fluorouracil ... | 18 Years - | Hoffmann-La Roche | |
| Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902029 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital, Essen | |
| A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) | NCT02788279 | Colorectal Canc... | Atezolizumab (M... Cobimetinib Regorafenib | 18 Years - | Hoffmann-La Roche | |
| Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation | NCT01959633 | Melanoma | Vemurafenib Peg-interferon Cobimetinib | 18 Years - | Fondazione Melanoma Onlus | |
| Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | NCT01495988 | Melanoma Metastatic Mela... | Vemurafenib Bevacizumab Cobimetinib | 18 Years - | Melanoma Research Foundation Breakthrough Consortium | |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | NCT02670044 | Leukemia, Myelo... | Cobimetinib Idasanutlin Venetoclax | 18 Years - | Hoffmann-La Roche | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | NCT05691504 | Advanced Endome... Metastatic Endo... Metastatic Fall... Metastatic Plat... Metastatic Prim... Recurrent Endom... Recurrent Fallo... Recurrent Plati... Recurrent Prima... Stage III Uteri... Stage IV Uterin... | Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pelcitoclax | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. | NCT04835805 | Melanoma | Belvarafenib Cobimetinib Nivolumab | 18 Years - | Genentech, Inc. | |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | NCT03224767 | BRAF V600E Muta... Papillary Crani... | Vemurafenib Cobimetinib Laboratory Biom... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer | NCT03340558 | Metastatic Colo... | Atezolizumab Cobimetinib | 18 Years - | Duke University | |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | NCT04941287 | Metastatic Dist... Metastatic Gall... Metastatic Intr... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage IV Distal... Stage IV Gallbl... Stage IV Intrah... Unresectable Li... | Atezolizumab Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Magnetic Resona... Varlilumab | 18 Years - | National Cancer Institute (NCI) | |
| A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | NCT03202940 | Non-small Cell ... | Alectinib Cobimetinib | 18 Years - | Massachusetts General Hospital | |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | NCT03600701 | Metastatic Lung... Recurrent Lung ... Refractory Lung... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | NCT02036086 | Melanoma | Vemurafenib Cobimetinib | 18 Years - | Sunnybrook Health Sciences Centre | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | NCT03108131 | Skin Squamous C... Appendix Adenoc... Rare Lesion Locally Advance... Locally Advance... Metastatic Mali... Metastatic Skin... Metastatic Smal... Rare Neoplastic... Refractory Mali... Stage IV Small ... Unresectable Ma... | Atezolizumab Cobimetinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | NCT02670044 | Leukemia, Myelo... | Cobimetinib Idasanutlin Venetoclax | 18 Years - | Hoffmann-La Roche | |
| Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | NCT02036086 | Melanoma | Vemurafenib Cobimetinib | 18 Years - | Sunnybrook Health Sciences Centre | |
| Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | NCT03175432 | BRAF V600 Wild ... Clinical Stage ... Intracranial Me... Metastatic Mali... Metastatic Mela... Pathologic Stag... Refractory Mela... | Atezolizumab Bevacizumab Cobimetinib Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | NCT02768207 | Metastatic Mela... | Cobimetinib Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | NCT02230306 | Active Melanoma... | Cobimetinib Vemurafenib | 18 Years - | University of Pittsburgh | |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC | NCT03363867 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Atezolizumab Bevacizumab Cobimetinib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | NCT02721459 | Melanoma Skin Cancer | XL888 Vemurafenib Cobimetinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma | NCT03554083 | Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... | Atezolizumab Cobimetinib Tiragolumab Vemurafenib | 18 Years - | Mayo Clinic | |
| A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | NCT03312530 | Multiple Myelom... | Cobimetinib Venetoclax Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | NCT03625141 | Metastatic Mela... | Cobimetinib Atezolizumab Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | NCT05034627 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... | Biopsy Calaspargase Pe... Cobimetinib | 18 Years - | OHSU Knight Cancer Institute | |
| A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | NCT03264066 | Solid Tumors | Cobimetinib Atezolizumab Atezolizumab Co... | 18 Years - | Hoffmann-La Roche | |
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations | NCT04409639 | Chronic Myelomo... | Cobimetinib | 18 Years - | University of Utah | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| Pre-operative Immunotherapy Combination Strategies in Breast Cancer | NCT03395899 | Breast Cancer Estrogen Recept... | Atezolizumab Cobimetinib Ipatasertib Bevacizumab | 18 Years - | Queen Mary University of London | |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | NCT04931342 | Ovarian Cancer | Ipatasertib Cobimetinib Trastuzumab Emt... Atezolizumab Bevacizumab Paclitaxel Giredestrant Abemaciclib Inavolisib Palbociclib Letrozole Olaparib Luteinizing Hor... Cyclophosphamid... Inavolisib | 18 Years - | Hoffmann-La Roche | |
| Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | NCT03181100 | Metastatic Thyr... Poorly Differen... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Thyroid Gland A... Unresectable Th... | Atezolizumab Bevacizumab Cobimetinib Nab-paclitaxel Paclitaxel Vemurafenib | 18 Years - | M.D. Anderson Cancer Center | |
| HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03284502 | Locally Advance... Metastatic Soli... | HM95573, cobime... HM95573, cetuxi... HM95573, cobime... HM95573, cetuxi... | 19 Years - | Hanmi Pharmaceutical Company Limited | |
| MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma | NCT04216953 | Sarcoma,Soft Ti... | Cobimetinib Atezolizumab | 12 Years - | Centre Leon Berard | |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC | NCT03363867 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Atezolizumab Bevacizumab Cobimetinib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | NCT02427893 | Melanoma | Cobimetinib Vemurafenib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | NCT02902029 | Malignant Melan... | Vemurafenib Cobimetinib Atezolizumab | 18 Years - | University Hospital, Essen | |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | NCT03498521 | Cancer of Unkno... | Alectinib Vismodegib Ipatasertib Olaparib Erlotinib Bevacizumab Vemurafenib Cobimetinib Trastuzumab Sub... Pertuzumab Atezolizumab Carboplatin Paclitaxel Cisplatin Gemcitabine Entrectinib Ivosidenib Pemigatinib | 18 Years - | Hoffmann-La Roche | |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | NCT03600701 | Metastatic Lung... Recurrent Lung ... Refractory Lung... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | NCT01974258 | Neoplasms | Cobimetinib Cobimetinib Onartuzumab Vemurafenib | 18 Years - | Hoffmann-La Roche | |
| Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | NCT03600701 | Metastatic Lung... Recurrent Lung ... Refractory Lung... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Cobimetinib Computed Tomogr... Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS | NCT01986166 | Neoplasms | Cobimetinib MEHD7945A | 18 Years - | Genentech, Inc. | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread | NCT02060188 | Microsatellite ... Microsatellite ... Mismatch Repair... Mismatch Repair... | Ipilimumab Nivolumab Cobimetinib Daratumumab BMS-986016 | 18 Years - | Bristol-Myers Squibb | |
| Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | NCT02230306 | Active Melanoma... | Cobimetinib Vemurafenib | 18 Years - | University of Pittsburgh | |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | NCT02091141 | Neoplasms Solid Tumors Biliary Cancer Salivary Cancer Bladder Cancer | Trastuzumab Pertuzumab Erlotinib Vemurafenib Cobimetinib Vismodegib Alectinib Atezolizumab | 18 Years - | Genentech, Inc. | |
| A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | NCT01271803 | Malignant Melan... | Cobimetinib vemurafenib | 18 Years - | Hoffmann-La Roche | |
| A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | NCT02908672 | Melanoma | Atezolizumab Atezolizumab Pl... Cobimetinib Vemurafenib Vemurafenib Pla... | 18 Years - | Hoffmann-La Roche | |
| Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | NCT03178851 | Malignant Melan... | Atezolizumab Cobimetinib Atezolizumab Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | NCT02721459 | Melanoma Skin Cancer | XL888 Vemurafenib Cobimetinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | NCT05159245 | Advanced Cancer Solid Tumor Haematological ... | Alectinib Cobimetinib Vismodegib Trastuzumab+Per... Entrectinib Atezolizumab Vemurafenib Regorafenib Apalutamide Abemaciclib Selpercatinib Dabrafenib Trametinib Dabrafenib+Tram... Pralsetinib | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Study of Cobimetinib in Participants With Solid Tumors | NCT00467779 | Solid Tumor | cobimetinib dextromethorpha... midazolam | 18 Years - | Genentech, Inc. | |
| A MolEcularly Guided Anti-Cancer Drug Off-Label Trial | NCT04185831 | Solid Tumor | Atezolizumab Everolimus Cobimetinib | 18 Years - | Uppsala University Hospital | |
| A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer | NCT03695380 | OVARIAN CANCER | Cobimetinib Niraparib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| Targeted Pathway Inhibition in Patients With Pancreatic Cancer | NCT04005690 | Locally Advance... Metastatic Panc... Stage II Pancre... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Cobimetinib Olaparib Onvansertib Azenosertib | 18 Years - | OHSU Knight Cancer Institute | |
| A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT02457793 | Non-Small Cell ... | Cobimetinib GDC-0994 | 18 Years - | Genentech, Inc. | |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | NCT04079179 | Langerhan's Cel... Juvenile Xantho... Erdheim-Chester... Rosai Dorfman D... Neuro-Degenerat... Histiocytic Sar... Histiocytic Dis... | Cobimetinib | - | Baylor College of Medicine | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
